Prosensa to Appoint Michael Wyzga to Supervisory Board
Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding
N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare
diseases with a high unmet medical need, today announced that Michael S. Wyzga
has been nominated for appointment to its Supervisory Board at the next
shareholders' meeting, scheduled for June 17, 2014.
"We welcome Michael as an instrumental addition to our Supervisory Board,"
said Hans Schikan, Prosensa's CEO. "Michael's extensive financial and
transactional expertise will support the company significantly in our efforts
to bring much-needed, life-saving treatments for rare genetic diseases to
patients. His long-term tenure at Genzyme, one of the most successful
companies in the rare disease space, will be invaluable as we continue
developing therapies for boys with Duchenne muscular dystrophy and building
Mr. Wyzga most recently served as President and Chief Executive Officer of
Radius Health. Prior to joining Radius, Mr. Wyzga was Executive Vice President
and Chief Financial Officer of Genzyme Corporation until its $20.1 billion
acquisition by Sanofi in April 2011. He joined Genzyme in 1998 and held
primary responsibility for the company's financial management worldwide. Mr.
Wyzga currently serves on the board of directors for OncoMed Pharmaceuticals,
Akebia Therapeutics and Idenix Pharmaceuticals.
"Michael's corporate leadership experience in rare diseases makes him an ideal
fit for Prosensa, and his contribution will be vital as the company works to
successfully advance its DMD drug pipeline," said David Mott, Chairman of
Prosensa's Supervisory Board.
"I am pleased to join Prosensa at such a significant moment in the company's
history and look forward to working alongside a world-class team with
exceptional leadership in rare diseases," said Michael Wyzga. "It is an honor
to be able to share my experience and contribute to the future direction and
growth of a company working so diligently to find a therapeutic option for
boys with this devastating disease."
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the
discovery and development of RNA-modulating therapeutics for the treatment of
genetic disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's
Prosensa's current portfolio includes six compounds for the treatment of DMD,
all of which have received orphan drug status in the United States and the
European Union. The compounds use an innovative technique called exon-skipping
to provide a personalized medicine approach to treat different populations of
DMD patients. www.prosensa.com
CONTACT: Prosensa Holding N.V.
Celia Economides, Senior Director, IR & Corporate Communications
Phone: +1 917 941 9059
Prosensa Holding B.V. Logo
Press spacebar to pause and continue. Press esc to stop.